Palleon Pharmaceuticals and Shanghai Henlius Biotech have entered a licence agreement and partnership for the former’s ...

Zanubrutinib is under clinical development by BeiGene and currently in Phase II for Lupus Nephritis. According to GlobalData, Phase II drugs for Lupus Nephritis have a 50% phase transition success ...

Felzartamab is under clinical development by Biogen and currently in Phase I for Lupus Nephritis. According to GlobalData, Phase I drugs for Lupus Nephritis have an 84% phase transition success rate ...

In a new study published in Lupus Science & Medicine, researchers explored the efficacy of using a combination of belimumab and standard immunotherapy compared to standard immunotherapy alone in ...

The lupus nephritis market is poised for growth, driven by rising disease prevalence, advancements in therapeutics such as biologics and targeted therapies, and increased investment in R&D.

GLP-1 RAs might lower kidney failure risk in patients with lupus nephritis by reducing pro-inflammatory mediators. Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment in patients with ...

ACR 2024 highlighted new guidelines for the screening, treatment, and management of lupus nephritis, stressing prompt kidney biopsy and timely treatment.

"This collaboration marks a significant step forward in our mission to transform lupus nephritis treatment," said Dr. Alon Yaar, CEO of LIVEKIDNEY.BIO. "By joining forces with Isotopia, we are ...